Profound Medical (OTCQX:PRFMF; TSXV:PRN) has completed the acquisition of the Sonalleve MR-HIFU business from Royal Philips (NYSE:PHG; AEX:PHIA).Read More
Profound Medical (OTCQX:PRFMF; TSXV:PRN) has agreed to expand an existing collaboration with Royal Philips (NYSE:PHG; AEX:PHIA) and acquire Philips’ Sonalleve MR-HIFU business, establishing Profound as a market leader in magnetic resonance (MR) ultrasound ablation therapy.Read More
Profound Medical (OTCQX:PRFMF;TSXV:PRN) announced the first TULSA-PRO patient paid procedure has been successfully conducted at the ALTA Klinik in Bielefeld, Germany under the supervision of Dr. Agron Lumiani.Read More
Profound Medical (OTCQX:PRFMF; TSXV:PRN) has successfully completed the first sale of a TULSA-PRO system in Finland to the Turku University Hospital, in collaboration with Royal Philips, who is working in partnership with Profound to commercialize the TULSA-PRO system in Europe.Read More
Echelon Wealth Partners initiated coverage of Profound Medical (OTCQX:PRFMF; TSXV:PRN) with a “buy” rating and one-year price target of $4. The stock closed at 78 cents on March 14.Read More
Steven Plymale, president and COO of Profound Medical (TSX-V:PRN), has been appointed an independent director of XOR-Labs, a spinoff from Toronto General Hospital at University Health Network, the world's leading center for lung transplantation and a MaRS Innovation company.Read More
Mackie Research Capital raised its price target for Profound Medical (TSX-V:PRN) to $4.40 from $3.30 after the company reported third quarter results. The stock closed at $1 on Thursday.
Analyst Andre Uddin writes that his new valuation is based on applying a multiple of 4.2 times enterprise value to sales on a 2019 sales estimate to $86-million, discounted back by 50%.Read More
Profound Medical (TSX-V:PRN) has completed a bought deal offering of 15.82 million common shares at a price of $1.10 each for gross proceeds of about $17.4-million.
The offering was completed through a syndicate of underwriters led by GMP Securities, and included Echelon Wealth Partners and Mackie Research Capital.Read More
Profound Medical (TSX-V:PRN) has entered into an agreement with a syndicate of underwriters, led by GMP Securities, for a bought deal of 15.82 million common shares at a price of $1.10 each for gross proceeds of $17.4-million.
The company has agreed to grant underwriters an overallotment option to purchase up to an additional 2,373,000 common shares at the same price for 30 days following closing. The offering is expected to close on Nov. 14, subject to regulatory approvals.Read More
Profound Medical (TSX-V:PRN) and Royal Philips have signed a sales and marketing agreement that will advance the commercial launch of Profound’s TULSA-PRO, a minimally invasive system to ablate targeted prostate tissue.
Under the accord, the two companies will collaborate in the commercialization of TULSA-PRO in Europe followed by Canada, the U.S. and other markets, subject to regulatory clearance in those jurisdictions.Read More